{"filings":[{"id":536757,"accession_number":"0000816956-26-000057","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-05-20T12:30:27+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CONMED appoints two new directors from J&J and Boston Scientific; Board expands to nine","event_type":"leadership","confidence":"high","bullets":["Appointed Celine Martin (ex-J&J MedTech exec) and Jeff Mirviss (ex-Boston Scientific exec) to Board, effective July 1, 2026.","Martin to serve on Audit and Strategy Committees; Mirviss on Compensation and Governance Committees.","Appointed Kimberly Lockwood as Interim Corporate Controller and Principal Accounting Officer, effective June 1, 2026.","Stockholders elected seven directors, approved say-on-pay, and ratified PwC as auditor for fiscal 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99034,"accession_number":"0000816956-26-000051","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance","event_type":"earnings","confidence":"high","bullets":["Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.","GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.","FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.","Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.","GI product exit impacted sales by $15.5M; company focusing on higher-growth areas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114827,"accession_number":"0001213900-26-027658","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CONMED names VP & Corporate Controller Andrew Moller as Interim Principal Financial Officer","event_type":"leadership","confidence":"high","bullets":["Andrew Moller, 51, appointed Interim Principal Financial Officer effective March 15, 2026.","Moller joined CONMED Jan 2025 as VP, Corp Controller; became Principal Accounting Officer Apr 2025.","Previously Global Controller & CFO Asia-Pacific at Smith & Nephew; prior roles at Stanley Black & Decker.","No change in compensation or related-party transactions for Moller's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114826,"accession_number":"0000816956-26-000006","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS","event_type":"earnings","confidence":"high","bullets":["Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.","FY2025 sales $1.3747B (+5.2%); GAAP EPS $1.51 vs $4.25, adjusted EPS $4.59 vs $4.17.","FY2026 guidance: revenue $1.345B-$1.375B (organic constant-currency growth 4.5%-6% ex-gastro), adj. EPS $4.30-$4.45.","International Q4 revenue +17% (reported) vs domestic +1.4%; Orthopedic Surgery segment +13.2%.","GAAP results weighed by ~$60M in Q4 operating charges including optimization and product rationalization."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1374724000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114825,"accession_number":"0001174947-26-000024","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CONMED provides preliminary 2026 guidance at J.P. Morgan Healthcare Conference; no figures in filing","event_type":"other_material","confidence":"low","bullets":["Presented at J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026.","Preliminary 2026 financial guidance was included in the investor presentation.","No specific revenue, EPS, or other guidance figures were disclosed in the filing text.","Presentation available on CONMED's website under Investors > Presentations.","CFO Todd W. Garner and CEO Pat J. Beyer presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114824,"accession_number":"0001174947-26-000017","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026","event_type":"leadership","confidence":"high","bullets":["Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.","Garner eligible for severance under Executive Severance Plan: 1.5x salary + 1.5x average bonus; equity continues vesting through Separation Date.","Company retained executive search firm for permanent CFO; separation not due to disagreement on operations, policies, financial results.","Garner will receive base salary and pro-rated bonus during advisory period but will not receive annual equity grant in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131208,"accession_number":"0001213900-25-118476","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026","event_type":"other_material","confidence":"high","bullets":["Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.","Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.","Consolidated gross margin expected to improve by ~80 bps after exit completion.","CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.","2026 guidance to be provided on Q4 2025 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131207,"accession_number":"0000816956-25-000054","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback","event_type":"earnings","confidence":"high","bullets":["Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.","Adjusted diluted EPS $1.08 vs $1.05 YoY; full-year adjusted EPS guidance raised to $4.48-$4.53.","Full-year revenue guidance narrowed to $1.365B-$1.372B; tariffs expected to reduce Q4 EPS by ~$0.07.","Board authorized $150M share repurchase program; quarterly cash dividend suspended; at least $25M annual buybacks from 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":1001526000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147798,"accession_number":"0001174947-25-001185","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025","event_type":"leadership","confidence":"high","bullets":["Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.","He serves on Corporate Governance & Nominating and Strategy Committees.","Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.","Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).","Prior roles include Thermo Fisher Scientific and Becton Dickinson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147797,"accession_number":"0000816956-25-000031","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CONMED declares $0.20 quarterly dividend, payable Oct 3, 2025","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20 per share declared on August 7, 2025.","Payable on October 3, 2025, to shareholders of record as of September 15, 2025.","No change in dividend amount from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147796,"accession_number":"0000816956-25-000026","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance","event_type":"earnings","confidence":"high","bullets":["Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).","Single-use products +6.6% to $297.8M; capital products -15.5% to $44.5M.","FY revenue guidance raised to $1.356B-1.378B; adj EPS raised to $4.40-4.55 (prior $4.31-4.46).","Company estimates ~$0.09 EPS headwind from tariffs in H2 2025.","Operational optimization consulting fees $7.6M in Q2; exec transition costs $12.2M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":663600000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147795,"accession_number":"0001174947-25-000987","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CONMED director Martha Aronson resigns to become Merit Medical President & CEO","event_type":"leadership","confidence":"high","bullets":["Martha Aronson resigned from CONMED board effective July 7, 2025 to become President and CEO of Merit Medical Systems.","No disagreement between Aronson and CONMED; resignation for external opportunity.","Aronson served on CONMED board since 2016 and previously served as Chair.","Chair LaVerne Council thanked Aronson for her strategic contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166493,"accession_number":"0001174947-25-000941","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CONMED enters into $750M credit agreement; maturities extended to 2030","event_type":"debt","confidence":"high","bullets":["New $550M USD revolver, $100M multicurrency revolver, and $100M term loan; maturity date June 10, 2030.","Proceeds used to repay existing term loan ($100M) and $16M of revolving amounts under prior credit agreement.","Removed fixed charge coverage ratio; added minimum interest coverage ratio of 2.75:1 (tested quarterly).","Removed mandatory prepayments on excess cash flow and updated interest rate margins (e.g., Term Benchmark Loans at 1.125% p.a.).","Credit agreement includes senior secured leverage ratio ≤3.75:1 and total leverage ratio ≤5.50:1 with step-ups for acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166492,"accession_number":"0001174947-25-000828","cik":816956,"company_name":"CONMED Corp","ticker":"CNMD","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"CONMED declares $0.20 dividend; shareholders approve 2025 LTIP and reelect directors","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.20/share declared, payable July 3, 2025 to holders of record June 13, 2025.","Eight directors reelected at May 20 annual meeting; each received >28M votes for election.","Advisory say-on-pay passed with 27.9M for, 0.9M against, 25.6K abstentions.","2025 Long-Term Incentive Plan approved with 22.0M for, 6.8M against, 25.1K abstentions.","Ratification of PwC as fiscal 2025 auditor approved with 27.7M for, 2.0M against, 6.4K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}